The cell and gene therapy clinical trials market is rapidly advancing, fueled by rising R&D investment, strong interest in cancer therapies, and growing regulatory support. With a forecasted CAGR of 15.09% through 2034, this market reflects the next frontier in precision medicine and life sciences innovation.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell and Gene Therapy Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell and Gene Therapy Clinical Trials Market, by Phase
8.1.1. Phase I
8.1.1.1. Market Revenue and Forecast
8.1.2. Phase II
8.1.2.1. Market Revenue and Forecast
8.1.3. Phase III
8.1.3.1. Market Revenue and Forecast
8.1.4. Phase IV
8.1.4.1. Market Revenue and Forecast
9.1. Cell and Gene Therapy Clinical Trials Market, by Indication
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast
9.1.3. CNS
9.1.3.1. Market Revenue and Forecast
9.1.4. Musculoskeletal
9.1.4.1. Market Revenue and Forecast
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast
9.1.6. Dermatology
9.1.6.1. Market Revenue and Forecast
9.1.7. Endocrine, Metabolic, Genetic
9.1.7.1. Market Revenue and Forecast
9.1.8. Immunology & Inflammation
9.1.8.1. Market Revenue and Forecast
9.1.9. Ophthalmology
9.1.9.1. Market Revenue and Forecast
9.1.10. Hematology
9.1.10.1. Market Revenue and Forecast
9.1.11. Gastroenterology
9.1.11.1. Market Revenue and Forecast
9.1.12. Others
9.1.12.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Phase
10.1.2. Market Revenue and Forecast, by Indication
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Phase
10.1.3.2. Market Revenue and Forecast, by Indication
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Phase
10.1.4.2. Market Revenue and Forecast, by Indication
10.2. Europe
10.2.1. Market Revenue and Forecast, by Phase
10.2.2. Market Revenue and Forecast, by Indication
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Phase
10.2.3.2. Market Revenue and Forecast, by Indication
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Phase
10.2.4.2. Market Revenue and Forecast, by Indication
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Phase
10.2.5.2. Market Revenue and Forecast, by Indication
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Phase
10.2.6.2. Market Revenue and Forecast, by Indication
10.3. APAC
10.3.1. Market Revenue and Forecast, by Phase
10.3.2. Market Revenue and Forecast, by Indication
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Phase
10.3.3.2. Market Revenue and Forecast, by Indication
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Phase
10.3.4.2. Market Revenue and Forecast, by Indication
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Phase
10.3.5.2. Market Revenue and Forecast, by Indication
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Phase
10.3.6.2. Market Revenue and Forecast, by Indication
10.4. MEA
10.4.1. Market Revenue and Forecast, by Phase
10.4.2. Market Revenue and Forecast, by Indication
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Phase
10.4.3.2. Market Revenue and Forecast, by Indication
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Phase
10.4.4.2. Market Revenue and Forecast, by Indication
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Phase
10.4.5.2. Market Revenue and Forecast, by Indication
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Phase
10.4.6.2. Market Revenue and Forecast, by Indication
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Phase
10.5.2. Market Revenue and Forecast, by Indication
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Phase
10.5.3.2. Market Revenue and Forecast, by Indication
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Phase
10.5.4.2. Market Revenue and Forecast, by Indication
11.1. IQVIA
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. ICON Plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Laboratory Corporation of America Holdings
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Charles River Laboratories International, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. PAREXEL International Corp.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Syneos Health
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medpace Holdings, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. PPD Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novotech
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Veristat, LLC
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description